Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Final OS results from INAVO120 show inavolisib plus palbociclib and fulvestrant significantly improves survival, delays ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen appeared well tolerated, according to investigators. Perspective from Antoinette R.

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE ®) to current standard-of ...

The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...